{"protocolSection":{"identificationModule":{"nctId":"NCT00684515","orgStudyIdInfo":{"id":"P05005"},"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)","officialTitle":"Phase II Study of SCH 530348 in Subjects With Cerebral Infarction"},"statusModule":{"statusVerifiedDate":"2018-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-09-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2007-11-08","type":"ACTUAL"},"completionDateStruct":{"date":"2007-11-08","type":"ACTUAL"},"studyFirstSubmitDate":"2008-05-22","studyFirstSubmitQcDate":"2008-05-22","studyFirstPostDateStruct":{"date":"2008-05-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-05-09","resultsFirstSubmitQcDate":"2014-07-28","resultsFirstPostDateStruct":{"date":"2014-07-29","type":"ESTIMATED"},"dispFirstSubmitDate":"2008-10-09","dispFirstSubmitQcDate":"2009-10-21","dispFirstPostDateStruct":{"date":"2009-10-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-08-22","lastUpdatePostDateStruct":{"date":"2018-09-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction. The study will assess incidence and tolerability of bleeding, major adverse cardiac events, all adverse events, and effect on expression of markers of inflammation."},"conditionsModule":{"conditions":["Cerebral Infarction"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":90,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vorapaxar 2.5 mg + Aspirin","type":"EXPERIMENTAL","description":"Vorapaxar oral tablets; once daily for 60 days + Aspirin.","interventionNames":["Drug: Vorapaxar 2.5 mg","Drug: Aspirin 75-150 mg"]},{"label":"Vorapaxar 1 mg + Aspirin","type":"EXPERIMENTAL","description":"Vorapaxar oral tablets; once daily for 60 days + Aspirin.","interventionNames":["Drug: Vorapaxar 1 mg","Drug: Aspirin 75-150 mg"]},{"label":"Placebo + Aspirin","type":"PLACEBO_COMPARATOR","description":"Placebo oral tablets; once daily for 60 days + Aspirin","interventionNames":["Drug: Placebo","Drug: Aspirin 75-150 mg"]}],"interventions":[{"type":"DRUG","name":"Vorapaxar 2.5 mg","description":"Oral tablets; once daily for 60 days.","armGroupLabels":["Vorapaxar 2.5 mg + Aspirin"]},{"type":"DRUG","name":"Vorapaxar 1 mg","description":"Oral tablets; once daily for 60 days","armGroupLabels":["Vorapaxar 1 mg + Aspirin"]},{"type":"DRUG","name":"Placebo","description":"oral tablets; once daily for 60 days","armGroupLabels":["Placebo + Aspirin"]},{"type":"DRUG","name":"Aspirin 75-150 mg","description":"oral tablets; once daily for 60 days","armGroupLabels":["Placebo + Aspirin","Vorapaxar 1 mg + Aspirin","Vorapaxar 2.5 mg + Aspirin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE)","description":"An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporarily associated with study drug administration, whether or not considered related to study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization. All MACE events were excluded from this analysis.","timeFrame":"Up to Day 121"}],"secondaryOutcomes":[{"measure":"Number of Paticipants Experiencing Thrombolysis in Myocardial Infarction (TIMI) Major, Minor, and Non-TIMI Bleeding Events","description":"Major TIMI bleeding was defined as any intracranial bleeding (excluding micohemorrhages \\<10 mm evident on magnetic resonance imaging \\[MRI\\]), clinical over signs of hemorrhge associated with a drop in hemoglobin \\>=5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in a hemoglobin drop of 3 to \\<5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI or Minor TIMI bleeding.","timeFrame":"Up to Day 60"},{"measure":"Number of Participants With MACE or Death","description":"The number of participants experiencing major cardiac events or death was evaluated up to Day 121. Major cardiac events were defined as nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization.","timeFrame":"Up to Day 121"},{"measure":"Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels By Study Visit","description":"Participant blood samples were collected to determine the median serum level of hs-CRP. hs-cRP levels reflect the underlying level of inflammation. The higher the level, the greater the disease burden.","timeFrame":"Up to Day 60"},{"measure":"Mean CD40 Ligand Levels By Study Visit","description":"Participant blood samples were collected to determine the mean serum level of CD40 ligand. CD40 ligand values represent the level of disease activation with a higher level of CD40 ligand indicating a greater underlying risk.","timeFrame":"Up to Day 60"},{"measure":"Mean Membrane-Bound P-Selectin Levels By Study Visit","description":"Participant blood samples were collected at Baseline, Day 30, and Day 60 to determine the mean level of membrane-bound p-selectin in the serum. Membrane-bound P-selectin levels reflect the underlying level of inflammation. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels.","timeFrame":"Up to Day 60"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women at least 18 years old with last cerebral infarction (excluding cardiogenic cerebral embolism) having occurred from 14 days to less than 1 year after onset (at the time of obtaining consent), with stable nervous system for more than 24 hours and known course of disease.\n* Participants confirmed to have cerebral infarction lesion by brain computerized tomography (CT) or magnetic resonance imaging (MRI).\n* Both of in-participant and out-participant\n* Willing to give appropriate informed consent and complete all study-related procedures and able to adhere to dosing and visit schedules.\n* Women of child-bearing potential (all postmenopausal women who are \\<1 year menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified study drug, and for 60 days after completion or discontinuation of the medication.\n\nExclusion Criteria:\n\n* Pregnancy and nursing patients (premenopausal women should have a negative pregnancy test result confirmed before enrollment)\n* Participant with any serious complication or any condition that the investigator feels that would cause a significant hazard to the participant if the study drug is administered.\n* Known hypersensitivity to any component of the study drug.\n* Participation in a study or use of an investigational study drug within 30 days before obtaining consent.\n* Member of the staff personnel directly involved with this study\n* Family member of the study staff.\n* History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days before obtaining consent.\n* History of cerebral hemorrhage.\n* Severe hypertension (systolic blood pressure \\>200 mmHg or diastolic blood pressure \\>110 mmHg).\n* Major surgery within 2 weeks before obtaining consent.\n* Known platelet count \\<100,000/mm\\^3\n* Participants confirmed to have cerebral bleeding or any causes of cerebral bleeding by brain CT or MRI.\n* Participants with transient ischemic attack (TIA), progressive stroke or cardiogenic cerebral embolism.\n* Known impairment of renal function (serum creatinine \\>2.0 mg/dL \\[\\>176.8 (umol/L\\]), dysproteinemia, nephrotic syndrome, or other renal disease\n* Active or chronic hepatobiliary system or hepatic disease, or aspartate aminotransferase (GOT) or alanine aminotransferate (GPT) activity more than two times greater than the upper limit of the laboratory normal range.\n* Participants with contraindictation to aspirin.\n* Scheduled to have PCI (peripheral coronary intervention), peripheral interventional event, carotid endarterectomy, intra- and extra- cranial bypass surgery and intravascular surgery (angioplasty) during the study period.\n* Combination therapy with unfractionated heparin, tissue plasminogen activator, urokinase, warfarin, factor Xa inhibitor, direct thrombin inhibitor or antiplatelet agents other than aspirin after obtaining consent, or scheduled to have the above combination therapy.\n* Any serious impairment which would make detection of new ischemic events difficult (eg, bedridden participants, participants with total nursing care, dementia participants, etc.) or consciousness disturbance which may cause aspiration of the study drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"referencesModule":{"references":[{"pmid":"20947374","type":"RESULT","citation":"Shinohara Y, Goto S, Doi M, Jensen P. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis. 2012 May;21(4):318-24. doi: 10.1016/j.jstrokecerebrovasdis.2010.09.005. Epub 2010 Oct 14."}],"availIpds":[{"type":"CSR Synopsis","url":"http://www.merck.com/clinical-trials/study.html?id=P05005&kw=P05005&tab=access"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"FG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"FG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"28"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"27"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Protocol-Defined Clinical Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"BG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"BG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"90"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.0","spread":"10.0"},{"groupId":"BG001","value":"65.8","spread":"11.6"},{"groupId":"BG002","value":"63.7","spread":"8.9"},{"groupId":"BG003","value":"64.3","spread":"10.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"21"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"69"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE)","description":"An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporarily associated with study drug administration, whether or not considered related to study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization. All MACE events were excluded from this analysis.","populationDescription":"The population consisted of all enrolled participants that received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Day 121","groups":[{"id":"OG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"OG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"OG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"22"}]}]}]},{"type":"SECONDARY","title":"Number of Paticipants Experiencing Thrombolysis in Myocardial Infarction (TIMI) Major, Minor, and Non-TIMI Bleeding Events","description":"Major TIMI bleeding was defined as any intracranial bleeding (excluding micohemorrhages \\<10 mm evident on magnetic resonance imaging \\[MRI\\]), clinical over signs of hemorrhge associated with a drop in hemoglobin \\>=5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in a hemoglobin drop of 3 to \\<5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI or Minor TIMI bleeding.","populationDescription":"The population consisted of all enrolled participants that received at least one dose of study drug and had TIMI bleeding data available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Day 60","groups":[{"id":"OG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"OG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"OG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"}]}],"classes":[{"title":"Major TIMI Bleeding","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Minor TIMI Bleeding","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Non-TIMI Bleeding","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MACE or Death","description":"The number of participants experiencing major cardiac events or death was evaluated up to Day 121. Major cardiac events were defined as nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization.","populationDescription":"The population consisted of all enrolled participants that received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Day 121","groups":[{"id":"OG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"OG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"OG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"}]}],"classes":[{"title":"MACE","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels By Study Visit","description":"Participant blood samples were collected to determine the median serum level of hs-CRP. hs-cRP levels reflect the underlying level of inflammation. The higher the level, the greater the disease burden.","populationDescription":"The population consisted of all enrolled participants who received at least one dose of study drug and had hs-CRP data available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/L","timeFrame":"Up to Day 60","groups":[{"id":"OG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"OG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"OG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"}]}],"classes":[{"title":"Baseline (n=33, 29, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"1.44"},{"groupId":"OG001","value":"0.67","spread":"1.66"},{"groupId":"OG002","value":"0.56","spread":"1.06"}]}]},{"title":"Day 7 (n=32, 28, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"2.33"},{"groupId":"OG001","value":"0.49","spread":"0.73"},{"groupId":"OG002","value":"0.41","spread":"0.58"}]}]},{"title":"Day 14 (32, 29, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"2.69"},{"groupId":"OG001","value":"0.62","spread":"0.79"},{"groupId":"OG002","value":"0.44","spread":"0.72"}]}]},{"title":"Day 30 (n=31, 28, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"3.95"},{"groupId":"OG001","value":"0.55","spread":"1.07"},{"groupId":"OG002","value":"0.56","spread":"0.95"}]}]},{"title":"Day 45 (n=29, 27, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.09"},{"groupId":"OG001","value":"0.48","spread":"0.74"},{"groupId":"OG002","value":"0.59","spread":"0.76"}]}]},{"title":"Day 60 (n=29, 26, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"0.58"},{"groupId":"OG001","value":"0.53","spread":"0.63"},{"groupId":"OG002","value":"0.61","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Mean CD40 Ligand Levels By Study Visit","description":"Participant blood samples were collected to determine the mean serum level of CD40 ligand. CD40 ligand values represent the level of disease activation with a higher level of CD40 ligand indicating a greater underlying risk.","populationDescription":"The population consisted of all enrolled participants that received at least one dose of study drug and had CD40 ligand data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/L","timeFrame":"Up to Day 60","groups":[{"id":"OG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"OG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"OG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"}]}],"classes":[{"title":"Baseline (n=33, 29, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"0.62"},{"groupId":"OG001","value":"8.3","spread":"0.77"},{"groupId":"OG002","value":"5.9","spread":"0.62"}]}]},{"title":"Day 7 (n=32, 28, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"0.71"},{"groupId":"OG001","value":"5.8","spread":"0.74"},{"groupId":"OG002","value":"5.6","spread":"0.60"}]}]},{"title":"Day 14 (n=32, 29, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"0.64"},{"groupId":"OG001","value":"6.5","spread":"0.79"},{"groupId":"OG002","value":"6.6","spread":"0.66"}]}]},{"title":"Day 30 (n=31, 28, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.79"},{"groupId":"OG001","value":"7.1","spread":"0.78"},{"groupId":"OG002","value":"5.9","spread":"0.60"}]}]},{"title":"Day 45 (n=29, 27, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"0.77"},{"groupId":"OG001","value":"5.7","spread":"0.77"},{"groupId":"OG002","value":"6.2","spread":"0.54"}]}]},{"title":"Day 60 (n=29, 26, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"0.82"},{"groupId":"OG001","value":"5.3","spread":"0.76"},{"groupId":"OG002","value":"6.0","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Mean Membrane-Bound P-Selectin Levels By Study Visit","description":"Participant blood samples were collected at Baseline, Day 30, and Day 60 to determine the mean level of membrane-bound p-selectin in the serum. Membrane-bound P-selectin levels reflect the underlying level of inflammation. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels.","populationDescription":"The population consisted of all enrolled participants that received at least one dose of study drug and had membrane-bound p-selectin data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Arbitrary Units","timeFrame":"Up to Day 60","groups":[{"id":"OG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days."},{"id":"OG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days."},{"id":"OG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"classes":[{"title":"Baseline (n=2, 1, 3)","categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"0.80"},{"groupId":"OG001","value":"19.5","spread":"NA","comment":"Due to the sample size of 1 participant, calculation of the SE was not possible."},{"groupId":"OG002","value":"17.4","spread":"1.06"}]}]},{"title":"Day 30 (n=2, 1, 3)","categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":"4.20"},{"groupId":"OG001","value":"16.6","spread":"NA","comment":"Due to the sample size of 1 participant, calculation of the SE was not possible."},{"groupId":"OG002","value":"17.1","spread":"1.10"}]}]},{"title":"Day 60 (n=2, 1, 3)","categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"0.05"},{"groupId":"OG001","value":"18.3","spread":"NA","comment":"Due to the sample size of 1 participant, calculation of the SE was not possible."},{"groupId":"OG002","value":"18.0","spread":"0.07"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Day 121","eventGroups":[{"id":"EG000","title":"Vorapaxar 1 mg","description":"Vorapaxar 1 mg tablets administered orally once daily for 60 days.","seriousNumAffected":1,"seriousNumAtRisk":33,"otherNumAffected":26,"otherNumAtRisk":33},{"id":"EG001","title":"Vorapaxar 2.5 mg","description":"Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.","seriousNumAffected":2,"seriousNumAtRisk":29,"otherNumAffected":24,"otherNumAtRisk":29},{"id":"EG002","title":"Placebo","description":"Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.","seriousNumAffected":3,"seriousNumAtRisk":28,"otherNumAffected":20,"otherNumAtRisk":28}],"seriousEvents":[{"term":"Arterial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Oesophageal Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Cerebellar Infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Hyperventilation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]}],"otherEvents":[{"term":"Haemorrhagic Diathesis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Supraventricular Extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Facial Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Feeling Abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Herpes Zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":33},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":28}]},{"term":"Subcutaneous Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Blood Creatine Phosphokinase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":28}]},{"term":"Blood Glucose Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Blood Potassium Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Blood Triglycerides Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Blood Urine Present","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Electrocardiogram QT Prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Occult Blood Positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":33},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":29},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":28}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Musculoskeletal Stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":28}]},{"term":"Cerebral Infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":28}]},{"term":"Cervicobrachial Syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]},{"term":"Haemorrhage Subcutaneous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":28}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":28}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":29},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":28}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Prior approval by the Sponsor is required before the results obtained in the clinical study can be made public by the investigator (sub-investigator) in a publication or at a medical meeting."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"C000530299","term":"Vorapaxar"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M232590","name":"Vorapaxar","asFound":"Dose-Response Relationship","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}